Wellington Partners

Wellington Partners is a premier pan-European life science investor with offices in Zurich and across Europe, providing capital to therapeutics, diagnostics, and medical device ventures. The firm is one of the long-standing names in European healthcare venture, with a multi-fund history backing companies that span the spectrum from early biotech platforms to clinical-stage device businesses. Their reputation rests on disciplined therapeutic-area selection and willingness to support companies through extended clinical development cycles.

Wellington invests across Series A, Series B, and Series C, with checks in the $1M to $5M range as a participating investor in larger syndicates, scaling commitment through follow-on rounds. Geographic scope is pan-European, with active deployment in Germany, Switzerland, the UK, and the Nordics, alongside selective US co-investments through specialist syndicates.

Founders should arrive with clinical data, a defined regulatory path, and a clear hypothesis on therapeutic differentiation. Expect detailed scientific and clinical diligence drawing on the firm’s network of medical advisors. Warm introductions via European specialist co-investors or KOLs in the relevant therapeutic area will materially improve initial reception.